chordin Inhibitors

The inhibitors listed target various signaling pathways and molecules that are potentially connected to the functional network of Chordin, particularly within the BMP signaling pathway and embryonic development processes. LDN-193189 and SB431542 target the BMP and TGF-β receptors, respectively. Since Chordin's primary role is to modulate BMP activity, inhibiting BMP receptors can have an indirect effect on the pathways regulated by Chordin. SIS3 inhibits Smad3, a critical transducer in the TGF-β/BMP signaling pathway. By modulating Smad3 activity, this inhibitor could influence Chordin's role in this pathway. Inhibitors targeting Gremlin, NOGGIN, and Follistatin affect other BMP antagonists, providing an indirect approach to study and modulate pathways where Chordin is involved. Wnt/β-Catenin and Hedgehog pathway inhibitors (XAV-939 and Cyclopamine) target critical developmental and signaling pathways, which might indirectly affect Chordin's role in these processes. VEGF inhibitor, Bevacizumab, and JAK/STAT pathway inhibitor, Tofacitinib, target pathways involved in angiogenesis and cell signaling, respectively, which could intersect with Chordin-related processes. PI3K/Akt inhibitor, LY294002, targets another key signaling pathway, potentially influencing pathways associated with Chordin.